Atrial Fibrillation
This channel includes news and new technology innovations for the treatment of atrial fibrillation, also referred to as AF or afib. AF is a cardiac arrhythmia caused by irregular and often rapid heart rate. It is caused by the upper chambers (the atria) beating irregularly and uncoordinated with the lower ventricle chambers of of the heart. Symptoms include weakness with heart palpitations and shortness of breath. The conditional can lead to an increased risk of stroke and heart failure. AF episodes can cause the blood in the atria to stagnate and form clots, usually within the left atrial appendage (LAA). The clots can flow to the brain and cause a stroke. Treatments include anticoagulation therapy to dissolve clots, catheter or surgical ablation and LAA occlusion.
Videos | Atrial Fibrillation | March 21, 2019
Christine Albert, M.D., MPH, director of the Center for Arrhythmia Prevention at Brigham and Women’s Hospital, and...
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
March 19, 2019 — The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating...
The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.
Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.19...
Sponsored Content
OTC ECG devices can help detect abnormal heart rhythms in the general population, and this technology will continue to improve.
Feature | ECG | March 11, 2020
Apple created a stir when it announced in 2018 that its Apple Watch Series 4 was the first consumer health and fitness...
News | Wearables | March 18, 2019
March 18, 2019 — Researchers from the Stanford University School of Medicine presented preliminary results of the Apple...
News | Ablation Systems | February 04, 2019
February 4, 2019 – Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.
Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral...
Sponsored Content
Several wearable, less-obtrusive ECG monitors have been cleared by the FDA for longer wear. This example is Cardiac Insight’s Cardea SOLO device.
Feature | ECG | February 19, 2020
When the patients of Michael Boler, M.D. need cardiac monitoring, the Holter monitor is no longer his first choice. “...
News | EP Mapping and Imaging Systems | January 28, 2019
January 28, 2019 — Acutus Medical announced 12-month data from the UNCOVER-AF trial investigating the use of the AcQMap...
Technology | Ablation Systems | January 21, 2019
January 21, 2019 — Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force...
News | Atrial Fibrillation | December 18, 2018
December 18, 2018 — Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the...
Sponsored Content
Use of traditional Holter monitor leads can be an issue for patient compliance and comfort. The newer generation ambulatory cardiac monitors use a small, adhesive patch that sticks directly on the patient's chest and allows them to shower and go about daily activities without a belt mounted monitor or leads getting in the way. This is especially important for longer term monitoring of seven days or longer.
Feature | ECG | September 27, 2018
Advances in the technology of wearable cardiac monitors are improving both the experience of the patient and the...
News | Ablation Systems | November 30, 2018
November 30, 2018 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled...
Videos | EP Lab | November 15, 2018
Wilber Su, M.D., chief of cardiac electrophysiology, Banner University Medical Center, Phoenix, and clinical associate...
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines for Americans at the American Heart Association’s (AHA) 2018 Scientific Sessions this week. Chicago. It provides evidence-based recommendations for youth ages three through 17 and adults to safely get the physical activity and was a major topic of discussion. Pictured here is Russel Pate, Ph.D., Univerity Of South Carolina, chair of the National Physical Activity Plan Alliance, presenting on the main stage at AHA, with details relat d to the new guidelines.
Feature | AHA | November 20, 2018
November 7, 2018 — Here is a list of some of the key clinical trial presentations at the 2018 American Heart...
Sponsored Content
An example of the new generation of cardiac monitoring device that is replacing Holter monitoring is the Cardea Solo wearable sensor. The FDA-cleared device automatically analyzes data when the device is turned back into the physician's office and automatically produces a draft summary report. This technology can simplify the workflow by eliminating the need for third-party involvement.
Feature | Atrial Fibrillation | September 13, 2018
Rapid advances in technology to monitor atrial fibrillation (AF or Afib) are enabling clinicians to access real-time...
Technology | Ablation Systems | October 09, 2018
October 9, 2018 — Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for...
Use of traditional Holter monitor leads can be an issue for patient compliance and comfort. The newer generation ambulatory cardiac monitors use a small, adhesive patch that sticks directly on the patient's chest and allows them to shower and go about daily activities without a belt mounted monitor or leads getting in the way. This is especially important for longer term monitoring of seven days or longer.
Feature | ECG | September 27, 2018
Advances in the technology of wearable cardiac monitors are improving both the experience of the patient and the...
An example of the new generation of cardiac monitoring device that is replacing Holter monitoring is the Cardea Solo wearable sensor. The FDA-cleared device automatically analyzes data when the device is turned back into the physician's office and automatically produces a draft summary report. This technology can simplify the workflow by eliminating the need for third-party involvement.
Feature | Atrial Fibrillation | September 13, 2018
Rapid advances in technology to monitor atrial fibrillation (AF or Afib) are enabling clinicians to access real-time...
